Please assess the completion status of the following clinical trial:

Trial Title: Synergistic Enteral Regimen for Treatment of the Gangliosidoses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must have a documented infantile or juvenile gangliosidosis disease.~2. Age: 17 years or less at time of enrollment~3. Subjects and their caregivers must be willing to work with a ketogenic diet team for management of the subject's ketogenic diet.~Exclusion Criteria:~1. A desire to not participate~2. Patients who are older than 17 years will not be enrolled in this study.~3. Children with severe renal impairment will not be enrolled in this study.~4. Post-pubertal females who are pregnant, or who are unwilling to use highly-effective methods to prevent pregnancy, will be excluded from this study.~5. Breast-feeding females will be excluded from this study.~6. Subjects who have an allergy to miglustat or any of the components within the drug product will be excluded from this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 204 Months
- Healthy Volunteers: f

Study Arms:
- Syner-G Therapy Regimen (Type: EXPERIMENTAL): The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet, and daily treatment with orally-administered miglustat, for the duration of the 60-month study.

Based on this trial design, predict the completion outcome and termination type (if applicable).